Source: Blood Cancer Journal. Unidades: FM, ICB, FMRP
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE AGUDA, HOMEOSTASE, APOPTOSE, MITOCÔNDRIAS, ESPECTROMETRIA DE MASSAS, CROMATOGRAFIA LÍQUIDA, CÉLULAS-TRONCO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, Keli Cristina de et al. The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy. Blood Cancer Journal, v. 12, p. 1-11, 2022Tradução . . Disponível em: https://doi.org/10.1038/s41408-022-00747-w. Acesso em: 06 nov. 2024.APA
Lima, K. C. de, Martins, D. A. P., Miranda, L. B. L. D., Silva, J. L. C., Leandro, G. da S., Weinhäuser, I., et al. (2022). The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy. Blood Cancer Journal, 12, 1-11. doi:10.1038/s41408-022-00747-wNLM
Lima KC de, Martins DAP, Miranda LBLD, Silva JLC, Leandro G da S, Weinhäuser I, Cavaglieri R de C, Leal A de M, Silva WF da, Lange APA de L, Velloso EDRP, Rego EM, Griessinger E, Hilberink JR, Ammatuna E, Huls G, Schuringa JJ, Machado Neto JA. The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy [Internet]. Blood Cancer Journal. 2022 ; 12 1-11.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1038/s41408-022-00747-wVancouver
Lima KC de, Martins DAP, Miranda LBLD, Silva JLC, Leandro G da S, Weinhäuser I, Cavaglieri R de C, Leal A de M, Silva WF da, Lange APA de L, Velloso EDRP, Rego EM, Griessinger E, Hilberink JR, Ammatuna E, Huls G, Schuringa JJ, Machado Neto JA. The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy [Internet]. Blood Cancer Journal. 2022 ; 12 1-11.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1038/s41408-022-00747-w